The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626001246370
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
5/08/2026
Date registered
Help: Date registered
14/10/2026
Date last updated
Help: Date last updated
14/10/2026
Date data sharing statement initially provided
Help: Data sharing statement date
14/10/2026
Type of registration
Help: Type of registration
Retrospectively registered

Titles & IDs
Public title
Preventing intra-uterine infection and neonatal sepsis treatment failure in CALD communities: Precision antibiotic therapy through pathogen genomics (observational phase).
Scientific title
Feasibility of antenatal metagenomic screening to detect multidrug-resistant pathogens and guide precision antibiotic treatment for maternal and neonatal infection (observational phase).
Additional trial identifiers [1] 316041 0
2024 MRFF Genomics Health Futures Application ID: 2045399
Universal Trial Number (UTN)
Trial acronym
PreNEST
Related trial records

Health condition
Health condition(s) studied:
Neonatal sepsis 339897 0
Chorioamnionitis 343064 0
Pregnancy-related infection 343234 0
Condition category
Condition code
Infection 336133 336133 0 0
Other infectious diseases
Reproductive Health and Childbirth 339340 339340 0 0
Fetal medicine and complications of pregnancy

Intervention/exposure
Study type
Observational
Patient registry
False
Target follow-up duration
Target follow-up type
Description of the intervention or exposure
We will compare a metagenomic analysis with the standard microscopy, culture and sensitivity (MCS) testing that is currently performed on vaginal swabs from pregnant women at high risk of chorioamnionitis and whose infants are at high risk of neonatal sepsis.
The swabs will be collected in the same manner, by the same clinician, at the same time as the routine swab (MCS for clinical care). This will occur whenever the participant needs to have a routine swab performed, which varies between participants, and is decided by their clinician not study investigators or protocol. The number of swabs taken for metagenomic analysis will match the number taken for their routine care i.e., if one swab is taken for their routine care, one swab will be taken for metagenomic analysis, if two are taken for routine care, two will be taken for metagenomic analysis etc.

Briefly, for the metagenomic analysis samples will undergo shotgun metagenomic sequencing using Oxford Nanopore sequencing (ONT). Following removal of poor quality and human DNA, prespecified organisms will be detected using Kraken2. Resistance marker detection will involve metagenome alignment against a list of clinically relevant antimicrobial resistance (AMR) genes.
Intervention code [1] 335071 0
Diagnosis / Prognosis
Description of the comparator or control
Our metagenomic analysis will be compared with the results of standard microscopy, culture, and sensitivity (MCS) testing. The swabs will be collected in the same manner, by the same clinician, at the same time as the routine swab (MCS for clinical care). This will occur whenever the participant needs to have a routine swab performed, which varies between participants, and is decided by their clinician not study investigators or protocol.


Briefly, MCS testing involves:
Microscopy - staining and observation of the microbes (e.g. bacteria, yeast).
Culture - microbes are grown in the laboratory and observed/identified.
Sensitivity - if a pathogen of concern is identified following microscopy and culture, sensitivity testing will be performed to determine the most appropriate antibiotic to be used.
Control group
Active

Outcomes
Primary outcome [1] 343673 0
Performance of vaginal swab metagenomic testing for detection of Group B Streptococcus (GBS).
Timepoint [1] 343673 0
Cumulative data from the entire study cohort will be assessed at the conclusion of the study.
Primary outcome [2] 346586 0
Performance of vaginal swab metagenomic testing for detection of E. coli.
Timepoint [2] 346586 0
Cumulative data from the entire study cohort will be assessed at the conclusion of the study.
Primary outcome [3] 346588 0
Acceptability of metagenomic vaginal swab testing.
Timepoint [3] 346588 0
The questionnaire will be administered 3 - 6 weeks following enrolment and collection of the participants first vaginal swab sample.
Secondary outcome [1] 456277 0
Performance of vaginal swab metagenomic testing for the detection of culturable microbes.
Timepoint [1] 456277 0
Cumulative data from the entire study cohort will be assessed at the conclusion of the study.
Secondary outcome [2] 456278 0
Ability to provide data in an appropriate timeframe relative to treatment decisions.
Timepoint [2] 456278 0
Cumulative data from the entire study cohort will be assessed at the conclusion of the study.
Secondary outcome [3] 456281 0
Scalability and economic value (composite outcome).
Timepoint [3] 456281 0
Cumulative data from the entire study cohort will be assessed at the conclusion of the study.
Secondary outcome [4] 466512 0
Detection of clinically relevant pathogens (reasonably expected to inform clinical care). This outcome contributes to the overall assessment of of whether metagenomic testing can provide data that would not otherwise be available.
Timepoint [4] 466512 0
Cumulative data from the entire study cohort will be assessed at the conclusion of the study.
Secondary outcome [5] 466550 0
Detection of commensal loss. This outcome contributes to the overall assessment of of whether metagenomic testing can provide data that would not otherwise be available.
Timepoint [5] 466550 0
Cumulative data from the entire study cohort will be assessed at the conclusion of the study.
Secondary outcome [6] 466551 0
Detection of AMR determinants. This outcome contributes to the overall assessment of of whether metagenomic testing can provide data that would not otherwise be available.
Timepoint [6] 466551 0
Cumulative data from the entire study cohort will be assessed at the conclusion of the study.
Secondary outcome [7] 468819 0
Provision of useful and unambiguous data to non-specialist end users (clinicians).
Timepoint [7] 468819 0
Cumulative data from all interviews, conducted throughout the study period, will be assessed at the conclusion of the study.

Eligibility
Key inclusion criteria
Pregnant (>12 weeks gestation).
Able to provide informed consent for self.
Presenting to medical service at a study site with a suspected diagnosis of preterm premature rupture of membranes (PPROM; <37 weeks) and is undergoing high-vaginal swab testing (standard microscopy and culture) as part of the clinical visit.
Minimum age
18 Years
Maximum age
No limit
Sex
Females
Healthy volunteers
No
Key exclusion criteria
Not pregnant.
No clinical indication for vaginal swab due to suspected PPROM.
Not able to consent for self (E.g. minor, intellectual disability with guardian).

Study design
Purpose
Natural history
Duration
Cross-sectional
Selection
Defined population
Timing
Retrospective
Statistical methods / analysis
Current culture-based screening for vaginal swabs has a sensitivity between 70% to 85% and a specificity between 95% to 100%, with approximately 30% identifying pathogenic bacteria. Assuming these rates and a margin of 15% for clinically important screening of Group B Streptococcus (GBS) (i.e., the sensitivity of 70% for culture and 85% for metagenomic analysis), a sample size of 500 paired swabs will be required for a paired sample test of sensitivity at 80% power using a two-sided test (alpha=0.05) after accounting for 20% attrition. The sample sizes will be enough to detect a 6% margin of specificity (90% to 96%) at 80% power and alpha=0.05.

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
SA
Recruitment hospital [1] 29026 0
Flinders Medical Centre - Bedford Park
Recruitment postcode(s) [1] 45306 0
5042 - Bedford Park

Funding & Sponsors
Funding source category [1] 320642 0
Government body
Name [1] 320642 0
Australian Government Department of Health, Disability and Ageing, Medical Research Future Fund (MRFF)
Country [1] 320642 0
Australia
Primary sponsor type
University
Name
Flinders University
Address
Country
Australia
Secondary sponsor category [1] 323510 0
None
Name [1] 323510 0
Address [1] 323510 0
Country [1] 323510 0
Other collaborator category [1] 283801 0
Other
Name [1] 283801 0
SA Pathology
Address [1] 283801 0
Country [1] 283801 0
Australia
Other collaborator category [2] 283802 0
Hospital
Name [2] 283802 0
Flinders Medical Centre
Address [2] 283802 0
Country [2] 283802 0
Australia
Other collaborator category [3] 283803 0
Hospital
Name [3] 283803 0
Women's and Children's Hospital
Address [3] 283803 0
Country [3] 283803 0
Australia
Other collaborator category [4] 283804 0
Hospital
Name [4] 283804 0
Lyell McEwin Hospital
Address [4] 283804 0
Country [4] 283804 0
Australia
Other collaborator category [5] 283805 0
University
Name [5] 283805 0
Adelaide University
Address [5] 283805 0
Country [5] 283805 0
Australia
Other collaborator category [6] 283806 0
University
Name [6] 283806 0
University of the Sunshine Coast
Address [6] 283806 0
Country [6] 283806 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 319184 0
Southern Adelaide Clinical Human Research Ethics Committee
Ethics committee address [1] 319184 0
Ethics committee country [1] 319184 0
Australia
Date submitted for ethics approval [1] 319184 0
13/05/2025
Approval date [1] 319184 0
26/05/2025
Ethics approval number [1] 319184 0
2023/HRE00075

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 146522 0
Dr Lito Papanicolas
Address 146522 0
SA Pathology, Frome Rd, Adelaide, South Australia, 5000
Country 146522 0
Australia
Phone 146522 0
+61 8 8222 3253
Fax 146522 0
Email 146522 0
Contact person for public queries
Name 146523 0
Demi Georgiou
Address 146523 0
SA Pathology, Frome Rd, Adelaide, South Australia, 5000
Country 146523 0
Australia
Phone 146523 0
+61 498 652 538
Fax 146523 0
Email 146523 0
Contact person for scientific queries
Name 146524 0
Lito Papanicolas
Address 146524 0
SA Pathology, Frome Rd, Adelaide, South Australia, 5000
Country 146524 0
Australia
Phone 146524 0
+61 8 8222 3253
Fax 146524 0
Email 146524 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.